Prosecution Insights
Last updated: October 01, 2026

Examiner: KOSTURKO, GEORGE W

Tech Center 1600 • Art Units: 1621 1627 1628

This examiner grants 55% of resolved cases

Analysis

George W. Kosturko is an examiner in Tech Center 1600 and Art Unit 1621, where he has 727 resolved cases. The data shows an allowance rate of 54.6 percent and an interview lift of 48.9 percent. This lift indicates that applicants who conduct an interview see a higher probability of allowance than the baseline. The 48.9 percent interview lift suggests that direct communication is a tool for navigating the process.

The median days to allowance for these 727 resolved cases is 991. Practitioners should factor this 991-day timeline into their prosecution strategy. The 54.6 percent allowance rate provides a baseline for success in this art unit. With the resolved cases, the data offers a look at the examiner's historical performance.

In Art Unit 1621, the median days to allowance represents the time required to reach a grant. The interview lift is a metric for applicants to consider when deciding whether to engage the examiner directly. These figures establish the current prosecution environment for this examiner in Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

54.7%
Allow Rate
-5.3% vs TC avg
761
Total Applications
+49.0%
Interview Lift
990
Avg Prosecution Days
Based on 728 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
15.3%
§102 Novelty
40.8%
§103 Obviousness
24.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18817828 TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT Non-Final OA Genentech, Inc.
18554927 USE OF GOSSYPOL AND A METHANE INHIBITOR FOR REDUCING THE FORMATION OF METHANE EMANATING FROM THE DIGESTIVE ACTIVITIES OF RUMINANTS Non-Final OA DSM IP ASSETS B.V.
18800173 CARDIO- AND RENOSAFE ANTIDIABETIC THERAPY Non-Final OA Boehringer Ingelheim International GmbH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month